These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 4639347

  • 41. The metabolic changes after portacaval shunt.
    Martini GA.
    Acta Gastroenterol Belg; 1971 Feb; 34(2):216-31. PubMed ID: 5565413
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Early and late changes in fasting and absorptive plasma amino acids and ammonia after distal splenorenal shunt in cirrhosis.
    Trevisani F, Bernardi M, Arienti V, Scrivano P, Mazziotti A, Cavallari A, Patrono D, Piazzi S, Gozzetti G, Gasbarrini G.
    Hepatology; 1994 Feb; 19(2):329-38. PubMed ID: 8294090
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. [Ammonia intoxication in cirrhotics].
    Doxiades T, Baraloudis P, Sorokiadou D.
    Cah Anesthesiol; 1968 Mar; 16(2):171-9. PubMed ID: 5744226
    [No Abstract] [Full Text] [Related]

  • 48. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism.
    Rikkers L, Jenko P, Rudman D, Freides D.
    Gastroenterology; 1978 Sep; 75(3):462-9. PubMed ID: 680502
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Nitrogen metabolism after portacaval shunts in patients with cirrhosis. I. Effects of the operation upon the blood ammonia concentration.
    CHALMERS TC, HUGHES CW, IBER FL.
    AMA Arch Intern Med; 1958 Feb; 101(2):434-8. PubMed ID: 13497346
    [No Abstract] [Full Text] [Related]

  • 51. [Correction by L-dopa of neurologic manifestations of a chronic portocaval encephalopathy].
    Girard PF, Trillet M, Kopp N.
    Rev Neurol (Paris); 1972 Nov; 127(5):560-3. PubMed ID: 4668744
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. [Lactulose in the therapy of porto-systemic encephalopathy].
    Almici C, Inzoli MR, Poloni AE, Zambruni A.
    Minerva Med; 1973 Dec 05; 64(87):4596-603. PubMed ID: 4774227
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results.
    Vendemiale G, Palasciano G, Cirelli F, Altamura M, De Vincentiis A, Altomare E.
    Arzneimittelforschung; 1992 Jul 05; 42(7):969-72. PubMed ID: 1418064
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. [Propranolol, hepatic encephalopathy and blood levels of ammonia in hepatic cirrhosis].
    Errico M, Giacobbe A, Facciorusso D, Simone P, Conoscitore P, De Maio, Spirito F.
    Minerva Dietol Gastroenterol; 1987 Jul 05; 33(3):223-6. PubMed ID: 3670672
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.